Use access key #2 to skip to page content.

IBDvalueinvestin (99.67)

VANDA makes it to the Bigtime, too bad I can't pick it today due to caps delayed market caps rules.

Recs

0

May 07, 2009 – Comments (1) | RELATED TICKERS: VNDA

Ahead of the Bell: Vanda surges on Fanapt approval
Vanda shares soar after company says FDA approves schizophrenia drug following delay

 Related:

    * Johnson & Johnson
    * , Vanda Pharmaceuticals, Inc.

NEW YORK (AP) -- Shares of Vanda Pharmaceuticals Inc. skyrocketed in premarket trading Thursday after the company said regulators approved its schizophrenia drug Fanapt.
Related Quotes
Symbol    Price    Change
JNJ    54.12    -0.09
Chart for JOHNSON AND JOHNS DC
VNDA    9.26    +8.18
Chart for Vanda Pharmaceuticals Inc.

Rockville, Md.-based Vanda plans to begin shipping the drug to pharmacies later this year. The news sent Vanda shares surging nearly tenfold to $11.25 from $1.08. The stock last traded above $11 in November 2007, and has not been above $6.59 in the last year.

Fanapt, or iloperidone, was more effective than a sugar pill in controlling symptoms of schizophrenia in clinical testing. The drug is an atypical antipsychotic, a group of relatively new drugs. Other drugs in the group include risperidone, which Johnson & Johnson markets as Risperdal, and Eli Lilly & Co.'s Zyprexa.

Approval for the drug was delayed in July because the Food and Drug Administration concluded Fanapt was too similar to drugs already on the market. The agency also required more testing at the time.

The most common side effects for Fanapt in clinical testing were dizziness, dry mouth, fatigue, nasal congestion, sleepiness, low blood pressure, rapid heartbeat, and mild weight gain.

1 Comments – Post Your Own

#1) On May 07, 2009 at 10:03 AM, IBDvalueinvestin (99.67) wrote:

This is better than DNDN, because it got approved. DNDN still has yet to get approval

Report this comment

Featured Broker Partners


Advertisement